Ultragenyx Pharmaceutical (RARE) EBT Growth (3y) (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) EBT Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 9.34%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 40.43%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 12.01%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.05%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 86.16%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Ultragenyx Pharmaceutical 2.72 Bn 2.31 Bn 106.00 Mn -4.02%

Historic Data

Download Data
DateValue
Mar 31, 2026 -4.02%
Dec 31, 2025 7.41%
Sep 30, 2025 9.07%
Jun 30, 2025 10.28%
Mar 31, 2025 0.39%
Dec 31, 2024 -33.64%
Sep 30, 2024 -22.30%
Jun 30, 2024 -2.34%
Mar 31, 2024 -7.83%
Dec 31, 2023 -40.44%
Sep 30, 2023 -32.38%
Jun 30, 2023 -101.52%
Mar 31, 2023 -11.29%
Dec 31, 2022 -35.67%
Sep 30, 2022 -28.44%
Jun 30, 2022 -16.84%
Mar 31, 2022 -16.27%
Dec 31, 2021 79.62%
Sep 30, 2021 5.78%
Jun 30, 2021 -32.34%